Cartesian Therapeutics Inc (RNAC) Stock Price, Quote & News

Company Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile derma...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 348 8698

Website: www.cartesiantherapeutics.com

Address:

7495 New Horizon Way, Frederick, United States

judgeyoung2 Oct. 24 at 4:26 PM

$RNAC Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25

0 · Reply

YOLOartist Oct. 24 at 10:41 AM

$RNAC I’m with @kimgysen, kind of liberating to only have 11 of my 65k left after more than 5 years. Spread that pain out reeeal good. At this point, I could lose it all and just be happy that it’s over.

2 · Reply

kimgysen Oct. 23 at 5:11 PM

$RNAC Luckily the 2 of 17k left can't do much damage anymore

0 · Reply

kimgysen Oct. 23 at 1:41 PM

$RNAC Breaking even at 100+. I'd say oversold yes. RS + name change, not shady at all

0 · Reply

ThomasTrainTrader Oct. 22 at 7:02 PM

$RNAC Buying in a bit I picked up 8k shares today, RNAC is officially oversold looking at a target right now of around $14

1 · Reply

kimgysen Oct. 22 at 2:55 PM

$RNAC Almost back below 9 what?

0 · Reply

JF42 Oct. 21 at 11:21 AM

$RNAC no more CSO, company gets BO?

0 · Reply

kimgysen Oct. 20 at 5:32 PM

$RNAC Back above 10 bro what

0 · Reply

Stockswingalert Oct. 20 at 12:06 PM

$PRQR $RNA $RNAC $WVE $XBI https://www.stocktitan.net/news/PRQR/pro-qr-receives-cta-authorization-for-ax-0810-and-announces-virtual-4b4910ofj7dt.html

1 · Reply

kimgysen Oct. 17 at 6:35 PM

$RNAC Losing 9 too...

0 · Reply

Cartesian Therapeutics Announces New Employment Inducement Grant

Sep 9, 2025, 7:09 PM EDT - 6 weeks ago

Cartesian Therapeutics, Inc. (RNAC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 28, 2025, 7:00 AM EDT - 2 months ago

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Jun 3, 2025, 7:05 AM EDT - 5 months ago

Cartesian Therapeutics Announces New Employment Inducement Grants

May 30, 2025, 7:00 AM EDT - 5 months ago

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 8, 2025, 7:00 AM EDT - 6 months ago

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 8, 2025, 7:00 AM EDT - 7 months ago

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Apr 1, 2025, 7:00 AM EDT - 7 months ago

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Jan 27, 2025, 7:00 AM EST - 9 months ago

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

Dec 3, 2024, 6:00 AM EST - 11 months ago

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

Nov 21, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

Nov 10, 2024, 12:26 PM EST - 1 year ago

Cartesian Therapeutics: Uncertainty Remains

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Sep 17, 2024, 9:45 AM EDT - 1 year ago

Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

Jul 2, 2024, 12:55 PM EDT - 1 year ago

Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data

Jul 2, 2024, 6:40 AM EDT - 1 year ago

Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study

Jul 2, 2024, 6:31 AM EDT - 1 year ago

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

Jul 2, 2024, 6:31 AM EDT - 1 year ago

Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

Jul 2, 2024, 6:30 AM EDT - 1 year ago

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

May 22, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

May 13, 2024, 4:30 PM EDT - 1 year ago

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 8, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Apr 4, 2024, 7:30 AM EDT - 1 year ago

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Mar 7, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 5, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland

judgeyoung2 Oct. 24 at 4:26 PM

$RNAC Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25

0 · Reply

YOLOartist Oct. 24 at 10:41 AM

2 · Reply

kimgysen Oct. 23 at 5:11 PM

$RNAC Luckily the 2 of 17k left can't do much damage anymore

0 · Reply

kimgysen Oct. 23 at 1:41 PM

$RNAC Breaking even at 100+. I'd say oversold yes. RS + name change, not shady at all

0 · Reply

ThomasTrainTrader Oct. 22 at 7:02 PM

$RNAC Buying in a bit I picked up 8k shares today, RNAC is officially oversold looking at a target right now of around $14

1 · Reply

kimgysen Oct. 22 at 2:55 PM

$RNAC Almost back below 9 what?

0 · Reply

JF42 Oct. 21 at 11:21 AM

$RNAC no more CSO, company gets BO?

0 · Reply

kimgysen Oct. 20 at 5:32 PM

$RNAC Back above 10 bro what

0 · Reply

Stockswingalert Oct. 20 at 12:06 PM

$PRQR $RNA $RNAC $WVE $XBI https://www.stocktitan.net/news/PRQR/pro-qr-receives-cta-authorization-for-ax-0810-and-announces-virtual-4b4910ofj7dt.html

1 · Reply

kimgysen Oct. 17 at 6:35 PM

$RNAC Losing 9 too...

0 · Reply

Stockswingalert Oct. 17 at 4:50 AM

$PRQR $RNA $RNAC $WVE $XBI

0 · Reply

Stockswingalert Oct. 17 at 4:49 AM

$PRQR $RNA $RNAC $WVE $XBI $$$

0 · Reply

abcdzepeda Oct. 9 at 4:43 PM

$RNAC we should be getting the data for SLE (LUPUS) phase 2 trial any day now, and if the data is good, the stock price should move up quite dramatically. This could be the turning point this ticker has needed to get Wall Street on board with their technology.

2 · Reply

kimgysen Oct. 8 at 2:15 PM

$RNAC Wtf bro stay above 10

0 · Reply

Stockswingalert Oct. 8 at 12:13 PM

$RNAC 86% and Nhod 98% accurate But I never miss when I text people 😏😏😏 cc $PRQR $RNA $WVE $XBI from $70’s 💰💰💰💰

0 · Reply

kimgysen Oct. 7 at 4:20 PM

$RNAC Motherf* Springer do something

1 · Reply

Goodstockday Oct. 6 at 9:21 PM

$RNAC All the data suggests they are going to have a great drug for MG. That will bring a payday. Add in other conditions like Lupas and there is potential for more growth.

0 · Reply

kimgysen Oct. 6 at 8:16 PM

$RNAC I'm so selling this if this goes over and back below 10 one more time

1 · Reply

FunCoupons00 Oct. 3 at 3:38 PM

$MNKD $RNAC $XBI Just getting warmed up Q4 🚀

0 · Reply

FunCoupons00 Sep. 30 at 4:27 PM

$RNAC classic 4th quarter rotation for Bio’s & Pharma… $MNKD $XBI

1 · Reply

FunCoupons00 Sep. 30 at 2:47 PM

$MNKD Q4 tomorrow I think bio’s/pharma turn a new leaf $MNKD $RNAC

0 · Reply

kimgysen Sep. 25 at 1:59 PM

$RNAC I mean come on bruv it's time to do something lol

0 · Reply

Market Cap	238.18M
Revenue (ttm)	38.91M
Net Income (ttm)	-77.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-198.97%
Debt to Equity Ratio	0.00

Volume	68,500
Avg Vol	72,648
Day's Range	N/A - N/A
Shares Out	26.00M
Stochastic %K	29%
Beta	0.39
Analysts	Strong Sell
Price Target	$36.43